GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS
A securities class action lawsuit has been filed against GRAIL, Inc. (GRAL) after its NHS-Galleri Trial failed to meet its primary endpoint, resulting in a over $2.2 billion market capitalization loss. The lawsuit alleges that GRAIL misled investors by confidently promoting the trial's design and likely outcomes, despite knowing that the three-year follow-up period might be insufficient. Hagens Berman is investigating these claims and encouraging affected investors and individuals with knowledge of the trial to come forward.
Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Grail, Inc. (GRAL) shareholders who suffered losses to contact them regarding an upcoming August 4, 2026, deadline for a securities fraud class action lawsuit. The lawsuit alleges that Grail and its defendants made misleading statements between May 13, 2025, and February 19, 2026, failing to disclose issues with their NHS-Galleri Trial results which led to a significant stock price drop. Investors can inquire about their claims to recover losses under federal securities laws.
GRAL UPCOMING DEADLINE: Levi & Korsinsky Alerts Grail, Inc.
Levi & Korsinsky, LLP has alerted investors in Grail, Inc. (NASDAQ: GRAL) about a pending securities class action lawsuit. This action names senior executives, including CEO Robert P. Ragusa and President Joshua J. Ofman, as individual defendants, asserting they are liable under Section 20(a) of the Securities Exchange Act and for Sarbanes-Oxley certification violations. The lawsuit follows a significant stock price drop after Grail's NHS-Galleri trial failed, and the deadline for investors to apply for lead plaintiff appointment is August 4, 2026.
GRAL - GRAIL Inc Volatility & Greeks
This article provides a detailed financial overview of GRAIL Inc. (GRAL), including key metrics such as market capitalization, income, sales, various performance ratios, and stock performance indicators. It also lists insider and institutional ownership, analyst recommendations, and volatility measures. The data reflects the company's financial health, operational efficiency, and market sentiment, with the last close at $68.95.
Price to book forward of GRAIL, Inc. – NASDAQ:GRAL
This article displays the "Price to book forward" financial metric for GRAIL, Inc. (NASDAQ: GRAL). The content seems to be a financial data presentation page, showing the period, value, and change for this specific metric.
GRAIL integrates Galleri cancer test into Epic health records
GRAIL has announced a collaboration with Epic to integrate its Galleri multi-cancer early detection test into Epic's electronic health record platform. This integration, expected to be broadly available by the end of 2026, will allow approximately 450 health systems to order the test and manage patient data within existing EHR systems, aiming to streamline workflow and improve early cancer detection. Despite this positive development, InvestingPro analysis indicates that GRAIL's stock is currently overvalued, though the company maintains a strong current ratio.
Is NHS-Galleri Trial Miss and New Lawsuits Altering The Investment Case For GRAIL (GRAL)?
GRAIL, Inc. is facing securities class action lawsuits after its NHS-Galleri clinical trial failed to meet its primary endpoint, wiping out $2.2 billion in market value. This failure and the subsequent legal scrutiny challenge the company's investment narrative, raising concerns about data transparency and potential delays in regulatory approval and commercial adoption of its multi-cancer early detection test. Investors are now re-evaluating GRAIL's risk profile and the previously optimistic growth forecasts.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. is facing a securities class action lawsuit following a $2.2 billion market capitalization drop after its NHS-Galleri Trial failed to meet its primary endpoint on February 20, 2026. Hagens Berman Sobol Shapiro LLP is investigating claims that GRAIL misled investors regarding the trial's design and likelihood of success, particularly concerning the sufficiency of the three-year follow-up period. Investors who suffered losses between May 13, 2025, and February 19, 2026, are encouraged to contact the firm.
Price to sales forward of GRAIL, Inc. – NASDAQ:GRAL
The article displays the "Price to sales forward" metric for GRAIL, Inc. (NASDAQ: GRAL). This financial data point is presented within the context of TradingView's platform, indicating that the information is generated for analysis of the company's stock performance. The content is concise, focusing solely on this specific financial indicator and its presentation.
GRAL Court Reminder: GRAIL, Inc. Investors are Notified to Act before the Upcoming Securities Fraud Class Action Deadline on August 4
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives due to a significant stock drop following alleged misrepresentation regarding GRAIL's NHS-Galleri cancer trial. Investors are encouraged to act before the lead plaintiff deadline of August 4, 2026. The lawsuit claims GRAIL misled investors about the trial's design and its ability to meet the primary endpoint, leading to a 50.55% stock decline when the trial results did not show a statistically significant reduction in late-stage cancers.
Price to earnings forward of GRAIL Inc – SWB:NL0
This article provides financial data for GRAIL Inc (SWB:NL0) on the Stuttgart Stock Exchange, focusing on its price-to-earnings forward metric. The market was closed at the time of publication, showing no trades. The information is sourced from TradingView, with data provided by ICE Data Services and FactSet.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. is facing a securities class action lawsuit after its NHS-Galleri Trial failed to meet its primary endpoint, leading to a $2.2 billion market capitalization wipeout. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, are encouraged to come forward. The lawsuit alleges that GRAIL misled investors regarding the trial's design and its likelihood of success.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall ...
The Schall Law Firm is reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit alleging securities fraud. Investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, are encouraged to contact the firm by August 4, 2026. The lawsuit claims GRAIL made false and misleading statements regarding its NHS-Galleri trial, concealing adverse facts about the trial's effectiveness and overstating its optimism.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of GRAIL, Inc. (NASDAQ: GRAL) to participate in a class action lawsuit alleging securities fraud. The lawsuit claims that Grail made false and misleading statements about the prospects of its NHS-Galleri trial, concealing adverse facts and overstating optimism. Investors who purchased securities between May 13, 2025, and February 19, 2026, have until August 4, 2026, to contact the firm.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) concerning alleged securities fraud between May 13, 2025, and February 19, 2026. The lawsuit claims Grail made misleading statements about its NHS-Galleri trial, concealing adverse facts while overstating its prospects. Investors who suffered losses are encouraged to contact the firm before August 4, 2026.
GRAL Stock Price | Analyst Target 67.80 & Moderate Buy Consensus
Grail Inc (GRAL) currently trades at $69.11, with analysts giving it a "Moderate Buy" consensus and a price target of $67.80. The company has a market capitalization of $2.97 billion and a negative P/E ratio. Recent news includes a securities class action lawsuit and a prediction of the stock reaching $100 within a year.
GRAL Shareholder News: GRAIL, Inc. Accused of Making Misrepresentations about its Trial Results in Securities Fraud Class Action – Investors Notified to Contact BFA Law
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL made misrepresentations about its NHS-Galleri cancer trial results, leading to a 50.55% stock drop on February 20, 2026. Investors have until August 4, 2026, to contact Bleichmar Fonti & Auld (BFA) Law to discuss their legal options as lead plaintiff.
ROSEN, A LONGSTANDING FIRM, Encourages GRAIL, Inc.
The Rosen Law Firm is encouraging investors of GRAIL, Inc. (NASDAQ: GRAL) to secure legal counsel before the August 4, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements regarding its NHS-Galleri trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, may be entitled to compensation.
ROSEN, A LONGSTANDING FIRM, Encourages GRAIL, Inc.
The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements regarding its NHS-Galleri trial, potentially concealing issues that impacted the trial's ability to demonstrate a reduction in certain cancers. Investors are encouraged to contact the firm to join the class action.
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial. Investors who suffered losses have until August 4, 2026, to request to be appointed lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) due to alleged violations of federal securities laws. The lawsuit claims that Grail and its officers made misleading statements regarding the likelihood of success in its NHS-Galleri trial to detect Stage III–IV cancers. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.
GRAL Investors Have Rights – If You Lost Money Investing in
Robbins LLP has filed a class action lawsuit on behalf of investors who purchased shares of Grail, Inc. (NASDAQ: GRAL) between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail misled investors regarding the success probability of its NHS-Galleri study for early cancer detection. This follows a significant 50.55% stock price drop after Grail announced the trial failed its primary endpoint on February 19, 2026.
INVESTOR DEADLINE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) for investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail and its executives made false and misleading statements regarding the probability of achieving the primary endpoint in their NHS-Galleri trial. Investors who suffered substantial losses have until August 4, 2026, to seek appointment as lead plaintiff.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. (GRAL) is facing a securities class action lawsuit after its NHS-Galleri Trial failed to achieve its primary endpoint, leading to a substantial $2.2 billion market capitalization drop. Hagens Berman is investigating claims that GRAIL misled investors about the trial's design and likelihood of success. The lawsuit covers investors who purchased shares between May 13, 2025, and February 19, 2026, and a lead plaintiff deadline is set for August 4, 2026.
GRAL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Grail (NASDAQ: GRAL) about the August 4, 2026, deadline to seek the role of lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Grail made false and misleading statements regarding the likelihood of success of its NHS-Galleri trial, specifically concerning the statistically significant reduction in Stage III & IV cancers. This led to a dramatic 50.55% drop in Grail's stock price on February 19, 2026, after the company announced the trial's primary endpoint was not met.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
Hagens Berman has initiated a securities class action lawsuit against GRAIL, Inc. (GRAL) following a significant drop in its market capitalization due to the failure of its NHS-Galleri Trial to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors about the trial's design and its likelihood of success in detecting early-stage cancer. Investors who purchased GRAIL shares between May 13, 2025, and February 19, 2026, and suffered substantial losses, are encouraged to come forward.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
Pomerantz LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant drop in its stock price. This legal action comes after Grail announced that its NHS-Galleri Trial did not achieve its primary endpoint of statistically significant Stage III-IV reduction, causing its stock to fall over 50%. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.
GRAL DEADLINE: Levi & Korsinsky Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP reminds investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, which failed to achieve its primary endpoint, causing a significant stock drop of 50.55%. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and suffered losses may be eligible to join the lawsuit.
GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026
Bernstein Liebhard LLP announces a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors who suffered losses between May 13, 2025, and February 19, 2026, to join. The deadline to serve as lead plaintiff is August 4, 2026. The lawsuit alleges that GRAIL made false and misleading statements about its business, leading to artificially inflated stock prices and investor losses.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. (NASDAQ: GRAL) is facing a securities class action lawsuit after its NHS-Galleri Trial failed to achieve its primary endpoint, leading to a $2.2 billion market capitalization drop. Hagens Berman is investigating allegations that GRAIL misled investors about the trial's design and likelihood of success, particularly concerning the sufficiency of the three-year follow-up period. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered substantial losses are encouraged to come forward.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL
Rosen Law Firm is encouraging investors of GRAIL, Inc. (NASDAQ: GRAL) to secure legal counsel before the August 4, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that GRAIL made misleading statements regarding its NHS-Galleri trial, concealing that the trial's duration was insufficient to demonstrate the achievement of a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, may be entitled to compensation.
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is inviting shareholders of Grail, Inc. (GRAL) who experienced losses to participate in a securities fraud class action lawsuit. The lawsuit alleges that Grail's management made misleading statements between May 13, 2025, and February 19, 2026, regarding the achievability of primary endpoints in their clinical trials. Investors have until August 4, 2026, to apply to be lead plaintiff.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for securities fraud. The lawsuit alleges that Grail made false and misleading statements regarding its NHS-Galleri trial's effectiveness in reducing advanced cancers. Investors who purchased securities between May 13, 2025, and February 19, 2026, are encouraged to contact the firm before August 4, 2026, to potentially lead the lawsuit.
GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers for alleged violations of federal securities laws. The lawsuit seeks to recover damages for investors who purchased Grail securities between May 13, 2025, and February 19, 2026, alleging that defendants made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail's NHS-Galleri trial. Investors who suffered losses have until August 4, 2026, to request to be appointed as lead plaintiff.
$GRAL Notification: GRAIL, Inc. Accused of Misrepresentations about its Trial Results in Securities Fraud Class Action
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives due to alleged misrepresentations regarding its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors, leading to a significant 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint of reducing late-stage cancers. Investors have until August 4, 2026, to seek lead plaintiff status in the case.
INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, have until August 4, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Grail and its executive officers made false and misleading statements regarding the probability of achieving the primary endpoint in its NHS-Galleri trial, leading to a more than 50% drop in stock price when the trial's endpoint was not met. Investors with substantial losses are encouraged to contact Robbins Geller to learn more about leading the litigation.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. (GRAL) is facing a securities class action lawsuit after its NHS-Galleri Trial failed to meet its primary endpoint, leading to a $2.2 billion market capitalization drop. The lawsuit, led by Hagens Berman, alleges that GRAIL misled investors about the trial's design and its likelihood of success. The firm is investigating whether GRAIL's management knew that a three-year follow-up period was insufficient to achieve the trial's goal.
ROSEN, A LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL
The Rosen Law Firm is encouraging investors of GRAIL, Inc. (NASDAQ: GRAL) who purchased common stock between May 13, 2025, and February 19, 2026, to secure counsel before the August 4, 2026 lead plaintiff deadline. The firm is litigating a class-action lawsuit alleging that GRAIL made false and misleading statements regarding its NHS-Galleri trial, concealing issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors might be entitled to compensation without upfront fees.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Levi & Korsinsky, LLP reminds shareholders of Grail, Inc. (GRAL) about an upcoming lead plaintiff deadline of August 4, 2026, in a securities class action lawsuit. The lawsuit alleges that analyst optimism was based on misleading company representations regarding the NHS-Galleri trial, leading to a severe stock price collapse after disappointing trial results were announced. The firm is inviting investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, to determine their eligibility to recover losses.
Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for shareholders of Grail, Inc. (GRAL) who suffered losses between May 13, 2025, and February 19, 2026. The firm reminds investors of the August 4, 2026, lead plaintiff motion deadline in a class action lawsuit. The lawsuit alleges that Grail made misleading statements regarding its NHS-Galleri Trial results, leading to a significant stock price drop following an announcement that the primary endpoint was not met.
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
GRAIL, Inc. is facing a securities class action lawsuit after its NHS-Galleri Trial failed to meet its primary endpoint, causing a $2.2 billion market capitalization drop. The lawsuit alleges that GRAIL misled investors about the trial's design and its likelihood of success. Hagens Berman is investigating claims that the company's expressed optimism was unrealistic, given internal information suggesting the three-year follow-up period was insufficient.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025, and February 19, 2026, about their opportunity to act as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made misleading statements concerning its NHS-Galleri trial, failing to disclose that the trial was insufficient to demonstrate the achievability of reducing Stage III-IV cancers. Investors have until August 4, 2026, to move the Court to serve as lead plaintiff.
INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against GRAIL, Inc. (GRAL) for investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial, which aimed to show a reduction in late-stage cancers. Investors who suffered substantial losses have until August 4, 2026, to seek appointment as lead plaintiff.
Lead Plaintiff Deadlines of August 4, 2026 in Shareholder Class Action Lawsuits Against Grail, Inc. (GRAL), Verra Mobility Corporation (VRRM), and PicS N.V. (PICS) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC reminds investors about the August 4, 2026, deadline to apply as lead plaintiff in class action lawsuits against Grail, Inc. (GRAL), Verra Mobility Corporation (VRRM), and PicS N.V. (PICS). These lawsuits allege that the companies made materially false or misleading statements regarding their operations, revenue outlook, or IPO documents, leading to shareholder losses. Affected investors are encouraged to contact Holzer & Holzer to discuss their legal rights.
GRAL INVESTOR DEADLINE: GRAIL, Inc. Investors with
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made false and misleading statements regarding its NHS-Galleri trial's potential to achieve a statistically significant reduction in late-stage cancers, leading to a more than 50% stock price drop when results were announced. Investors with substantial losses have until August 4, 2026, to seek appointment as lead plaintiff.
Investor Announcement: GRAIL, Inc. Investors are Notified
Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. This action follows a 50% stock drop after GRAIL's NHS-Galleri cancer trial failed to meet its primary endpoint, allegedly due to the company misleading investors about the trial's design and timeline. Investors in GRAIL common stock are encouraged to contact BFA Law to discuss their rights, with a lead plaintiff deadline of August 4, 2026.
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock during the period of May 13, 2025, to February 19, 2026, about their opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL stock during this period may be entitled to compensation. The lawsuit alleges that GRAIL made misleading statements about its NHS-Galleri trial, concealing that the trial was insufficient to demonstrate a reduction in Stage III-IV cancers.
GRAL UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Grail (GRAL) about the August 4, 2026 deadline to act as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Grail made misleading statements about the success of its NHS-Galleri trial, which failed to achieve its primary endpoint of reducing Stage III-IV cancers. This announcement led to a dramatic 50.55% drop in Grail's stock price on February 20, 2026.
Will Samsung’s US$110 Million Asia-Focused Deal Transform GRAIL’s (GRAL) Multi-Cancer Test Narrative
GRAIL, Inc. has secured a US$110 million equity investment from Samsung affiliates, including Samsung C&T Corporation, to fund regulatory efforts for its Galleri multi-cancer early detection test and facilitate international expansion, particularly in South Korea and other Asian markets. This deal strengthens confidence in GRAIL's technology and provides capital for U.S. approval processes while addressing some funding concerns, though high cash burn and regulatory risks persist. The investment is expected to influence GRAIL's growth narrative, with analysts forecasting significant revenue and earnings increases by 2029.
GRAIL Inc Actuals & Estimates (BIVA:GRAL)
This article provides an overview of GRAIL Inc (GRAL) stock on BIVA, including its current price, market capitalization, volatility, and financial performance. It details analyst estimates for future price targets, past earnings, and future revenue projections, noting that the company does not pay dividends.
